SAN FRANCISCO, June 6, 2023 /PRNewswire/ — The global pea protein market size is expected to reach USD 4.7 billion by 2030, expanding at 12.0% CAGR from 2023 to 2030, according to a new report by grand view research, inc. The demand for pea protein is anticipated to be driven by several factors such as … Read more
BOSTON, June 6, 2023 /PRNewswire/ — Education Resources, Inc. (ERI) announces the launch of Toe Walking: In-Depth Clinical Applications-ON-DEMAND, a brand-new continuing education course for pediatric therapists, taught by ERI’s engaging and internationally renowned instructor, Liesa M. Ritchie-Persaud PT, DPT, PCS, CKTP. Toe Walking: In-Depth Clinical Applications – ON-DEMAND, which is available through ERI’s website, was … Read more
LEARN HOW TO ACTIVELY REDUCE STRESS THROUGH STIMULATION OF THE VAGUS NERVE ROCKAWAY, N.J., June 5, 2023 /PRNewswire/ — BACKGROUND:Ask any American if they are currently living with stress and the answer would likely be a resounding YES. Everybody agrees that stress makes life less enjoyable, and it isn’t hard to see how it might … Read more
“We are pleased with the results of the Phase 1 study which demonstrate a favorable safety profile for PRGN-3005 UltraCAR-T. Our UltraCAR-T therapies continue to be well-tolerated with no dose limiting toxicities across our clinical stage UltraCAR-T portfolio,” said Helen Sabzevari, PhD, President and CEO of Precigen. “At this early stage, we are encouraged that … Read more
LAKE FOREST, Calif., June 5, 2023 /PRNewswire/ — BIOLASE, Inc. (NASDAQ: BIOL) (“BIOLASE” or the “Company”), a global leader in dental lasers, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly-designated Series I Preferred Stock, par value $0.001 per share, for each outstanding share of BIOLASE common stock held of … Read more
-Dragonfly Therapeutics anuncia la presentación de la fase 1 de los resultados del aumento de dosis de DF1001 TriNKET® en la reunión anual de ASCO 2023 En la Sesión de Terapéutica del Desarrollo – Inmunoterapia de ASCO, el Dr. Howard Safran presenta datos alentadores sobre el estudio de fase 1/2 de Dragonfly de DF1001, un … Read more
PHILADELPHIA, June 5, 2023 /PRNewswire/ — In an effort to encourage individuals to work toward their weight loss goals this summer and beyond, Nutrisystem®, a division of Wellful, Inc. and leading provider of health and wellness and weight loss solutions, has launched the $100,000 Great Summer Giveaway and will award a total of 11 prizes. One … Read more
NERVIANO, Italy, June 5, 2023 /PRNewswire/ — Nerviano Medical Sciences S.r.l. (NMS), a clinical-stage biotechnology company member of NMS Group S.p.A. (NMS group), the largest cancer research and development company in Italy, announced signing of a license agreement and right of option with Solve Therapeutics, Inc. (SolveTx) to develop and commercialize novel antibody-drug conjugates (ADCs) … Read more
In der ASCO Developmental Therapeutics – Immunotherapy Session präsentiert Dr. Howard Safran ermutigende Daten zur Phase 1/2-Studie von Dragonflys DF1001, einem immunologischen TriNKET®, das auf HER2 bei Patienten mit fortgeschrittenen soliden Tumoren abzielt. WALTHAM, Mass., 5. Juni 2023 /PRNewswire/ — Dragonfly Therapeutics, Inc., ein im klinischen Stadium tätiges Biotechnologieunternehmen, das neuartige Immuntherapien entwickelt, gibt die … Read more
In the ASCO Developmental Therapeutics – Immunotherapy Session, Dr. Howard Safran presents encouraging data on Dragonfly’s phase 1/2 study of DF1001, an immune engaging TriNKET® targeting HER2 in patients with advanced solid tumors. WALTHAM, Mass., June 5, 2023 /PRNewswire/ — Dragonfly Therapeutics, Inc., a clinical stage biotechnology company developing novel immunotherapies, announces the first presentation of … Read more